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Background:  Eastern North Carolina has historically high prevalence rates of cardiovascular 
disease. Novel solutions such as mobile screening technology may aid in reaching this region’s 
vulnerable health population to prevent further disease progression. Additionally, symptoms of 
psychological distress are commonly comorbid with cardiovascular disease but often overlooked 
as formal predictors or modifiers of increased disease burden. Behavioral medicine providers 
recognize the importance of screening for psychological stress as it relates to cardiovascular 
disease as a way to reduce disease burden and advancement. Therefore, mobile-ECG screening 
for atrial fibrillation and exploration of adding psychological variables to a well-established 
cardiovascular stroke risk calculator (CHA₂DS₂-VASc) are discussed. 
 
Methods:  Participants (N = 250) were approached at pharmacies in Eastern North Carolina. 
Participants completed demographic and medical history questionnaires, the DASS-21, and were 
administered a single-lead mobile-ECG (mECG). All mECG readings were interpreted by the 
mECG device in addition to adjudication by three electrophysiologists. Medical referrals were 
provided when indicated. Chi-squared statistics were utilized to investigate regional rates of 
atrial fibrillation and associated risk factors. Binary logistic regression modeling measured the 
capability of the CHA₂DS₂-VASc stroke risk calculator to predict abnormal mECG readings both 
with and without the addition of DASS-21 symptom scores. 
 
Results:  Rates of previously undiagnosed atrial fibrillation were much higher than rates found in 
studies of similar scope and design. Participants’ average CHA₂DS₂-VASc scores (2.68 ± 1.35) 
signify an alarming rate of untreated ischemic stroke risk in a community sample. Additionally, 
the prevalence rates of six, known independent stroke risk factors were also significantly higher 
in the study sample than reported national US averages. Significant point-biserial correlations 
were not found between psychological endpoints and abnormal mECG readings or elevated 
CHA₂DS₂-VASc scores, but binary logistic regression modeling revealed that a longstanding 
stroke risk calculator could be potentially strengthened with the addition of one (anxiety) or three 
(depression, anxiety, and stress) psychological endpoints. 
 
Discussion:  The results of the current study further the knowledge of the utility of using mobile-
health techniques to capture previously undiagnosed atrial fibrillation and associated risk factors. 
Prevalence of chronic disease and other health metrics in the Eastern North Carolina region are 
substantially worse than the general US population. Additionally, the results presented begin a 
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CHAPTER 1:  INTRODUCTION 
 
 Atrial fibrillation (AFib) is a chronic cardiac condition of abnormal heart rhythm 
affecting more than 45 million patients worldwide, and more than 6 million adults in the United 
States (US) (Du, Dong, Ma, 2017). AFib is caused by irregular beats by the two upper chambers 
of the heart (the atria), during a period of problematic synchronicity with the two lower chambers 
of the heart (the ventricles).  This type of arrhythmia can cause blood pooling susceptible to clot 
formation which can lead to cerebrovascular stroke. While AFib may have short-term symptoms, 
including shortness of breath and palpitations, its status as a primary risk factor for stroke is the 
greater public health concern (Morillo, Banerjee, Perel, Wood, Jouven, 2017). AFib is often 
under-diagnosed, as the symptoms may be inconsistent or misattributed to other comorbid 
disease states (January, Wann, Alpert, Calkins, Cigarroa, Conti et al., 2014). The feasibility and 
effectiveness of community-based screening for AFib is a new avenue with both population-wide 
and individual-level implications to further identify and address this burgeoning health problem. 
 Background:  Eastern North Carolina (ENC) has been identified as a potential “hot spot” 
for increased rates of AFib due to high prevalence rates of associated risk factors (Tchwenko, 
2012). It has been theorized that previously undiagnosed AFib rates may be significantly higher 
in this region, as compared to the national average, because of the elevated rates of comorbid 
disease states such as hypertension, obesity, and diabetes (Bennett, Coleman, Hayden, Holmes, 
Nelson, Puckett et al., 2012). The utilization of rapid, non-invasive mobile-electrocardiogram 
(mECG) technology may allow for more efficient AFib screenings for at-risk individuals who 
with no prior AFib diagnosis. Because of the dynamic disease continuum of AFib, it is 
imperative to investigate the psychological symptoms that AFib patients may experience. 




patients and healthcare providers during shared decision-making processes and may increase 
patient engagement and decrease overall cardiovascular burden. 
 Study Purpose:  Novel mECG technology has the ability to provide near-instant cardio-
feedback to individuals at risk for AFib. AliveCor, Incorporated (AliveCor, 2018) has developed 
an FDA-cleared device that records a single-channel mECG rhythm with contact of an 
individual’s fingertips. The mECG recordings are stored on the user’s mobile device, as well as 
on AliveCor’s encrypted servers, and can be printed or emailed to a health provider at any time. 
The mECG can currently report one of three heart rhythm statuses: (A) Normal, (B) Possible 
AFib, and (C) Indeterminable.  
 The purpose of the current study was to utilize mECG technology to detect previously 
undiagnosed AFib in individuals with two or more self-reported risk factors. Participants 
presenting to point-of-care pharmacies in rural, ENC were approached for study participation. A 
brief screening measure was used to determine participant eligibility, and collected data 
including demographics and self-reported AFib risk factors. mECG screenings were then 
administered to participants with two or more AFib risk factors. Negative AFib readings resulted 
in the patient receiving brief, verbal education on AFib and stroke, as well as a supplemental 
brochure. Positive AFib readings resulted in the patient receiving both educational support and a 
referral to a board-certified cardiologist and/or primary care provider of the participant’s 
preference. In addition to the AFib screening measure, the Depression Anxiety and Stress Scales 
– Short Form (DASS-21; Henry & Crawford, 2005) was administered to gather self-reported 




CHAPTER 2:  REVIEW OF LITERATURE 
Cardiovascular Disease 
  
 Cardiovascular disease (CVD) comprises a wide range of heart and vessel disorders. The 
most common forms of CVD include hypertension, coronary artery disease, CVA, congestive 
heart failure (CHF), and AFib (American Heart Association, 2017).  These conditions are often 
related and may be comorbid, resulting in significantly increased negative health outcomes 
(Benjamin, Blaha, Chiuve, Cushman, Das, Deo et al., 2017).  Improved medical knowledge and 
rapidly advancing health technology has led to decreased mortality rates in developed nations; 
however, aging populations and high prevalence of risk factors continue to cause the global 
burden of CVD to be significant (Okwuosa, Lewsey, Adesiyun, Blumenthal, & Yancy, 2016; 
Roth, Forouzanfar, Moran, Barber, Nguyen, Feigin et al., 2015).  CVD remains the leading cause 
of death worldwide, causing almost one third of total deaths (Okwuosa et al., 2016).  In the US, 
CVD is the leading cause of death for both men and women, and accounts for more deaths than 
cancer and lower respiratory diseases combined (Benjamin et al., 2017).  In 2015, more than 
40% of the US population had at least one form of CVD (American Heart Association, 2017).  
This figure is projected to rise to approximately 45% of the U.S. population by 2035 (Benjamin 
et al., 2017).  
 CVD has been linked to a number of risk factors, preventable and non-preventable. These 
include age, gender, family history, obesity, poor diet, lack of exercise, diabetes, high 
cholesterol, and tobacco use (Benjamin et al., 2017).  In the US, climbing rates of obesity and 
increasingly sedentary lifestyles have contributed to poor cardiovascular outcomes (Bennett, 
Coleman, Hayden, Holmes, Nelson, Puckett et al., 2012). Overall CVD rates in the US are 




2012).  Interestingly, there seems to be increasing geographical disparity regarding rates of CVD 
in American populations.  While CVD mortality rates have steadily declined in the New England 
and Mid-Atlantic regions, the South has retained high mortality rates (Singh, Azuine, Siahpush, 
Williams, 2015).  This is likely due to an increased concentration of those with one or more risk 
factors for CVD (Singh et al., 2015). Lastly, AFib and associated healthcare costs represent a 
significant financial burden in the US.  When health expenditures and lost productivity are 
accounted for, cardiovascular disease and stroke cost the US more than $300 billion per annum 
(Benjamin et al., 2017). 
Atrial Fibrillation 
 AFib is the most common cardiac arrhythmia worldwide affecting up to six million 
Americans, and this number is projected to double within the next 25 years (Du et al., 2017).  AFib 
can occur in brief, paroxysmal episodes or more regular intervals, and is a disease state typically 
classified according to the duration of the episode (January et al., 2014). Symptoms of AFib can 
be overt or covert and include irregular heartbeat, palpitations, dizziness, fatigue, shortness of 
breath, and chest pain (January et al., 2014). The most troublesome statistic repeatedly conveyed 
in the literature is that AFib may increase a person’s risk of ischemic stroke by five times 
(American Heart Association, 2017).  Additionally, developing the condition may triple your risk 
of heart failure (Stewart, Hart, Hole, & McMurray, 2002) and double your risk of major 
neurocognitive disorder (Ott et al., 1997).  For these reasons, the reduction of AFib prevalence and 
its associated risk factors continues to be an important public health objective. 
Early identification of AFib is becoming a priority issue in medicine because the 
accompanying poor outcomes are thought to be highly preventable when appropriate medical 




to AFib (Hannon et al., 2009), but AFib is asymptomatic in approximately 61% of patients (Barnett 
et al., 2016). A systematic review found that single timepoint screening is capable of identifying 
an overall AFib prevalence of 2.3%, and 4.4% in those individuals over the age of 65 (Lowres et 
al., 2013). Most importantly, they found a 1% incidence of previously undiagnosed AFib, a figure 
that increased to 1.4% in individuals 65 years of age and older (Lowres et al., 2013). Due to the 
heightened risk of stroke, myocardial infarction, and all-cause mortality that is known to be highest 
within months of initial diagnosis (Miyasaka et al., 2006), early diagnosis of AFib is paramount in 
medical settings (Atar et al., 2012). Therefore, medical technologies that permit and encourage 
more frequent screening for AFib may be extremely valuable. 
Risk factors for AFib. As hypertension, diabetes, and cardiovascular disease rates have 
risen in the US, the portion of the population at risk of AFib has also risen (Du et al., 2017). 
However, the prevalence rates of these risk factors are not evenly dispersed. Certain regions of 
the US show higher rates of comorbid risk factors, and there is overlap with the US “stroke belt” 
which cover 11 states in the southern US, including North Carolina (Tchwenko, 2012). Of all 
annual NC deaths in persons aged 65 and older, more than one-fourth of those individuals die as 
a result of CVD and cerebrovascular disease, with stroke being the fourth leading cause of death 
in the state (Purcell et al., 2012; Tchwenko, 2012). The eastern most counties of NC have had 
some of the highest stroke mortality rates in the US for more than 35 years (North Carolina 
Institute of Medicine, 2014). There are currently nine potentially modifiable risk factors that 
account for more than 90% of the risk of heart attacks and stroke in ENC, including the 
following: hypertension, abnormal lipids, current smoking, obesity, unhealthy diet, physical 
inactivity, type II diabetes, alcohol intake, and various psychological factors (Kulshreshtha, 




treatment of risk factors has been identified as a potential cornerstone to reduce the state’s 
cardiovascular disease burden. 
 Stroke risk stratification. Stroke represents the most injurious outcome that can be 
caused by AFib and one out of every twenty deaths in the US can be attributed to stroke (Ziegler, 
Glotzer, Daoud, Singer, Ezekowitz, Hoyt et al., 2012). Not only is AFib associated with a five 
times increased risk of stroke, but it is also associated with more severe and disabling stroke 
outcomes (American Heart Association, 2017). An individual’s stroke risk is calculated from 
summative scores comprised of heterogeneous risk factors; each assigned a point value. In the 
past, there have been various stratification systems used to classify stroke risk (Lip, 2013). These 
systems have traditionally been based on a combination of expert opinion, clinical research trials, 
and the evolution of known risk factors. The current gold-standard of stroke risk stratification is 
the CHA₂DS₂-VASc score (Table 1), which was preceded by the CHA₂DS₂ calculator.  
 The CHA₂DS₂ score, originally termed the Birmingham schema algorithm, was 
developed from a multicenter research trial (SPAF-1, 1991). At that time, use of the calculation 
tool was widely encouraged to medical practitioners around the world. Subsequent validation 
studies and the development of new research on independent stroke risk factors paved the way 
for an enhanced version of this tool, the CHA₂DS₂-VASc calculator (Lip, Nieuwlaat, Pisters, 
Lane, Crijns, 2010). The new version of the stroke risk calculator has been found to be more 
robust than the original version and takes into account more recently discovered risk factors such 
as female sex, advanced age, and vascular disease (Olesen, Lip, Hansen, Hansen, Tolstrup, 
Lindhardsen, 2011). Scores range from 0 to 9 with a higher score denoting increased stroke risk. 
The criteria contain two major risk factors worth 2 points each – the history of previous 




risk stroke patients, it is also able to more precisely discriminate low-risk patients disallowing 
incorrect or unnecessary medical treatment (Olesen & Torp-Pedersen, 2015). Accurate 
forecasting of an individual’s stroke risk continues to be imperative to guide treatment. As 
detection methods for AFib become more sophisticated, stroke risk calculators will most likely 
continue to evolve as well. Current research is now focusing on the addition of possible 
biomarkers and other psychological risk factors that could strengthen the predictive capability of 
the CHA₂DS₂-VASc score (Jabati, Fareed, Liles, Otto, Hoppensteadt, Bontekoe et al., 2018). 
Table 1. CHA₂DS₂-VASc Stroke Risk Calculator 
 
CHA₂DS₂-VASc  Score 
Congestive heart failure 1 
Hypertension 1 
Age ≥ 75 2 
Diabetes 1 
Previous stroke or TIA 2 
Vascular disease 1 
Age 65 – 74  1 
Female sex 1 
TOTAL 0 – 9  
 
 Screening with mECG. Traditional screening methods for AFib often require 
professional setup and operation such as a 12-lead electrocardiogram (ECG), or potentially 
burdensome wearable technologies and event recorders. The cost of these traditional methods of 
screening impose barriers to assessment and treatment for low SES individuals. Clinic-based 
screening before and after procedures is an important step in assessing the success of the 
procedure to guide management decisions for healthcare providers and patients (Calkins, Kuck, 
Cappato, Brugada, Camm, Chen et al., 2012). The early recurrence of AFib is common within 
the first three months of an ablation procedure and may predict high-risk patients who might 




al., 2012). Recently, several medical technology companies have developed relatively low cost 
and convenient ECG technology options leveraging patient smartphone and internet access. 
One of the major barriers to regular ECG screening is the time and inconvenience that is 
associated with getting a 12-lead reading (Orchard, Freedman, Lowres, Peiris, Neubeck, 2014). 
AliveCor, Incorporated has recently developed an innovative way to procure a 1-lead ECG using 
only a mobile device and a user’s fingertips (AliveCor, 2018). This device is a single lead, wireless 
ECG technology that connects to a free application on a user’s smartphone or tablet. Using the app 
and Bluetooth connectivity, users can take a 30-second reading of their heart rate, with immediate 
feedback on whether they may be experiencing an AFib episode. Users then have the option to 
forward their reading to cardiac care specialists. Participants in a pilot study in the ENC region 
reported high levels of technology satisfaction with the AliveCor device and reliably used the 
device as prescribed (Kropp, Ellis, Nekkanti, Sears, 2018). The associated AliveCor app can be 
found on all major mobile phone platforms.  
Community screening. A notable benefit of these new mECG technologies is their ease 
of application in non-traditional health settings. These devices allow for quick, accessible AFib 
screenings in locations that are highly utilized by at-risk individuals. Comparisons between mECG 
recordings and traditional trans-telephonic monitor recordings have revealed excellent agreement 
between the two methods (Tarakji, Wazni, Callahan, Kanj, Hakim, Wolski, 2015). mECG devices 
have demonstrated up to 100% sensitivity and 97% specificity rates for the detection of AFib and 
atrial flutter (Tarakji et al., 2015).  
Point-of-care locations such as pharmacies, primary care offices, and nursing homes have 
been identified as locations with high volumes of potentially at-risk patients that could benefit 




colleagues (2016) identified undiagnosed AFib rates of 1.5% in a population of 1,000 individuals. 
Nurses utilizing mECG technology at a flu walk-in clinic uncovered an overall prevalence rate of 
3.8% in a population of 973 individuals, and the screenings were rated as efficacious and timely 
by staff (Orchard, Lowres, Freedman, Ladak, Lee, Zwar et al., 2016). Other community-focused 
studies have compared mECG readings to traditional 12-lead ECGs and found high sensitivity 
(98%), specificity (97%), and overall accuracy (97%) of mECG devices (Galloway, Albert, 
Freedman, 2013). Non-governmental organizations, triage centers, and various outpatient 
locations have benefitted from the easy usability of mECG devices to complete screenings for 
individuals who otherwise would not have access. The further sophistication of these screening 
technologies will continue to make mECG tools ideal for community screening and the regular 
monitoring of ECG patients.  
Psychological Correlates of AFib 
 AFib is psychologically burdensome primarily because the symptoms can be ‘silent’ 
and/or unpredictable, while posing long-term, and possibly deadly, health risks including 
thromboembolic stroke. AFib can be particularly problematic in the post-operative period 
because of its association with increased mortality (Jung, Meyerfeldt, Birkmeyer, 2006), higher 
rate of stroke (Mariscalco, Lorusso, Klersy, Ferrarese, Tozzi, Vanoli et al., 2007), and longer 
hospital stays (Aranki, Shaw, Adams, Rizzo, Couper et al., 1996). The relationship between 
anxiety/depression and AFib is complex and decreasing AFib symptom severity does not always 
reduce psychological distress (Thompson, Barksdale, Sears, Mounsey, Pursell, Gehi, 2014). 
Rather, anxiety and depression are primarily conceptualized as exacerbating factors to common 
AFib symptoms (Thompson et al, 2014). These findings further increase the interest of 




 Psychological distress is frequently present in AFib patients (Wändell, Carlsson, Gasevic, 
Wahlström, Sundquist, 2016), and symptoms of depression and anxiety are associated with 
heightened symptom severity in AFib (Gehi, Sears, Goli, Walker, Chung, Schwartz, Mounsey, 
2012; Thompson et al., 2014; von Eisenhart-Rothe, Hutt, Baumert, Breithardt, Goette, Kirchhof 
et al., 2015). Multiple AFib risk factors (female sex, younger age, new-onset AFib) have been 
found to be independent predictors of overall lower QoL (Steinberg, Holmes, Ezekowitz, 
Fonarow, Kowey, Mahaffey et al., 2013). Symptoms of anxiety and depression have routinely 
been found to be associated with increased AFib symptom severity, and resistant to 
improvement, even when overall disease burden is lessened with antiarrhythmic drug therapy 
and catheter ablation (Thompson et al., 2014). Symptoms of depression and reported physical 
inactivity are closely correlated with worsened AFib outcomes (Garimella, Sears, Gehi, 2016). 
 Depression can be a significant mediator for poor health-related QoL outcomes in 
patients with coronary artery disease (Akintade, Chapa, Friedmann, Thomas, 2015), myocardial 
infarctions (Frasure-Smith, Lespérance, Habra, Talajic, Khairy, Dorian et al., 2009), and AFib 
(Ong, Irvine, Nolan, Cribbie, Harris, Newman et al., 2006). Symptoms of depression in CVD 
patients are known to worsen AFib-related symptoms, and men with AFib have been observed to 
be at 30% greater mortality risk when concomitant symptoms of depression are present 
(Akintade et al., 2015; Wändell et al., 2016). Patients with AFib are significantly more likely to 
be depressed (Dąbrowski, Smolis-Bąk, Kowalik, Kazimierska, Wójcicka, Szwed, 2010), and 
depression heightens recurrent risk in some AFib patients (Lange & Herrmann-Lingen, 2007). 
Many patients with AFib disengage in their daily activities and can develop maladaptive 
cognitions about their AFib symptoms – further contributing to a low mood state (Ong et al., 




excessive anxiety that often afflicts AFib patients. This persistent worry can lead to autonomic 
arousal, general restlessness, and even insomnia putting patients at further risk for developing 
depressive symptoms (Lane, Langman, Lip, Nouwen, 2009). 
 Anxiety symptoms occur in approximately 38% of all patients with AFib (Thrall, Lip, 
Carroll, Lane, 2007), and have been established as an independent risk factor of adverse cardiac 
events (Frasure-Smith & Lespérance, 2008). Symptoms of anxiety are often the principal 
affective response to an AFib diagnosis, and Lane and colleagues discovered prevalence rates of 
39%, 31%, and 36% occurring at baseline, 3-month, and 6-month time points in this population 
(Lane et al., 2009). These findings mirror prevalence rates of anxiety commonly found in ICD 
patients, a patient group with known psychological difficulties (Sears & Conti, 2002). Symptoms 
of anxiety are endorsed by more than half of patients with paroxysmal AFib at the time of the 
arrhythmia “attack” (Hansson, Madsen-Härdig, Olsson, 2004). One explanation of the 
relationship between AFib and anxiety is dysregulation of the autonomic nervous system, 
subsequently having effects on both the reduction of parasympathetic activity and increase in 
sympathetic activity (Carney, Freedland, Veith, 2005). Given the overlap of symptoms between 
AFib and anxiety (e.g. shortness of breath, palpitations), it is understandable that autonomic 
arousal symptoms have been shown to be associated with AFib (Thomas, Chapa, Friedmann, 
Durden, Ross, Lee et al., 2008).  
 Stress, in general, is associated with cortisol imbalances and hypertension both of which 
can be damaging to heart function (Graff, Prior, Fenger-Grøn, Christenson, Glümer, Larson et 
al., 2017). Some research has shown acute, episodic stress to be associated with CVD, 
particularly in myocardial infarction and sudden cardiac death (Li, Hansen, Mortensen, Olsen, 




relationship between general stress and AFib is lesser known, but several theories posit plausible 
explanations as to why stress could lead to AFib episodes. These theories include 
parasympathetic modulation, excessive sympathetic activity, and pro-inflammatory cytokines as 
possible physiologic mechanisms of stress related AFib symptoms (Graff et al., 2017). Cognitive 
appraisals of physical symptomology also have some effect on AFib-related symptoms, and 
psychological stress is the most commonly endorsed “trigger” for idiopathic arrhythmias (Li et 
al., 2002).  
 Negative emotions, such as anxiety and sadness, have been shown to precipitate 
ventricular arrhythmias and myocardial infarctions in limited sample studies (Lampert, Joska, 
Burg, Batsford, McPherson, Jain, 2002), and there is growing interest on negative emotions 
having the ability to trigger an AFib episode. Research findings include a significant unadjusted 
increase in the likelihood of an AFib episode when accompanied with the endorsement of 
sadness, anxiety, anger, or stress (Lampert et al., 2014). Furthermore, the endorsement of stress 
on an end-of-day summary report almost doubled the likelihood of an AFib episode the 
following day and an overall dose-response was observed for reported stress and AFib episodes 
(Lampert et al., 2014). In summary, a growing body of research is beginning to capture the 
possible role of psychological distress as an antecedent to AFib episodes. 
 AFib is a condition amenable to psychological intervention due to its number of 
modifiable risk factors. Symptoms of depression, anxiety, and stress may be contributory to the 
AFib disease state and/or exacerbating factors. Further research is needed in this area to 
determine which psychological symptoms, if any, are most inflammatory to the AFib disease 





Summary, Aims, & Hypotheses 
 The primary aim of the current study was to examine the base rates of known risk factors 
associated with AFib, to determine the average CHA₂DS₂-VASc stroke risk scores, and to 
uncover the rates of previously undiagnosed AFib in an ENC community sample (N = 250).  The 
secondary aim of the project was to evaluate the relationships between self-reported 
psychological symptoms and correlates of AFib and its risk factors (N = 157).  The third and 
final aim was to evaluate predictors of abnormal mECG readings (N = 157).  
 Aim 1:  To report on the prevalence of risk factors associated with AFib, calculated 
CHA₂DS₂-VASc stroke risk scores, and previously undiagnosed AFib incidence in a community 
sample of 250 participants.  Hypothesis 1a:  The prevalence rates reported in the community 
sample of at least three, grant specified AFib risk factors will be greater than reported national 
averages.  Hypothesis 1b: The rates of previously undiagnosed AFib discovered using the mECG 
device will be greater than 2%.  Hypothesis 1c: The average CHA₂DS₂-VASc score in the study 
sample will be greater than 2.  
 Aim 2:  To examine which psychological endpoints, if any, are significantly correlated 
with abnormal mECG readings and/or elevated CHA₂DS₂-VASc scores (≥ 2).  Hypothesis 2a: 
At least one psychological endpoint will be significantly correlated with abnormal mECG 
readings.  Hypothesis 2b: At least one psychological endpoint will be significantly correlated 
with elevated CHA₂DS₂-VASc scores (≥ 2).  
 Aim 3:  To evaluate the predictive capabilities of the CHA₂DS₂-VASc component parts 
and their relationship(s) with abnormal mECG readings.  mECG readings will be dichotomized 
into ‘Normal’ or ‘Abnormal’ categories.  Abnormal mECG readings will include both ‘Possible 




VASc model will predict abnormal mECG readings independently and significantly.  Hypothesis 
3b: The strongest psychological endpoint, when added to the pre-existing CHA₂DS₂-VASc 
component parts, will strengthen its predictive capability of abnormal mECG readings.
 
 
CHAPTER 3: METHOD 
Participants 
 Residents of ENC presenting to one of two point-of-care pharmacy locations were 
approached for study participation.  Individuals who denied any previous diagnosis of AFib or 
atrial flutter and also endorsed two or more AFib risk factors were offered a free mECG 
screening.  Consenting participants were also given educational materials on AFib, medical 
referrals when indicated, and were asked to complete brief psychological questionnaires.  Other 
eligibility requirements included being 18-years of age or older, self-reported reading ability at 
fifth grade or greater, and being able to fluently speak and understand English. 
Measures 
 An IRB-approved waiver of consent was approved to administer a screening 
questionnaire comprised of demographics and self-reported AFib risk factors prior to full study 
participation.  mECG screenings were administered to participants with two or more AFib risk 
factors.  Negative AFib readings resulted in the patient receiving education on AFib and stroke, 
and all participants were given a supplemental AFib brochure.  Positive AFib readings resulted 
in the patient receiving the aforementioned educational support, in addition to an appropriate 
referral to a board-certified cardiologist.  Additionally, positive readings were sent confidentially 
to a primary care physician or cardiologist of the participant’s choosing. 
 Medical and personal history variables.  Demographic and medical variables collected 
include age, sex, race, marital status, and formal education. Participants were asked to consent to 





 AFib eligibility screening.  A screening questionnaire quickly determined whether or not 
participants were eligible for study participation.  First, participants reported whether or not they 
had a pre-existing diagnosis of AFib or atrial flutter.  If they answered ‘No’ to the first question, 
they were asked to self-report on the presence of pre-specified AFib risk factors including the 
following:  congestive heart failure, hypertension, age, diabetes, previous stroke, peripheral 
vascular disease, sex, obstructive sleep apnea, and obesity.  If the participant endorsed two or 
more risk factors, they were eligible for the mECG screening and further study participation.  
 CHA₂DS₂-VASc.  A CHA₂DS₂-VASc score is a commonly-used stroke risk calculator 
that uses a 0 – 9 scoring method, with higher scores denoting higher stroke risk.  Points are 
assigned to certain characteristics as shown in Table 1.  Based on participants self-reported 
symptoms and diagnoses, each participant was assigned an overall stroke risk score. 
 DASS-21. The Depression Anxiety and Stress Scales – Short Form (DASS-21) is an 
empirically validated measure of the emotional states of depression, anxiety and stress with 
excellent reliability and validity (Lovibond & Lovibond, 1995).  The depression subscale 
assesses for symptoms of dysphoria, hopelessness, devaluation of life, self-deprecation, lack of 
interest, and anhedonia.  The anxiety subscale assesses for symptoms of autonomic arousal, 
skeletal-muscle effects, situational anxiety, and the subjective experience of being anxious.  
Lastly, the stress subscale assesses symptoms of difficulty relaxing, nervous arousal, 
agitation/irritability, and over-reactivity/impatience.  Cronbach’s alphas for the subscales in 
clinical samples has been found to be .94 (depression), .87 (anxiety), and .91 (stress) (Antony et 
al., 1998).  Both the full version of the DASS and the DASS-21 have been found to have good 
convergent and discriminant validity when compared to other widely used and validated 




offered the opportunity to complete the DASS-21 in addition to their mECG reading. A total of 
157/250 participants completed both the mECG recording and the DASS-2.  
Study Design 
 Procedure.  Following eligibility screening and informed consent, participants were 
administered a 1-lead mECG reading with an AliveCor KardiaMobile device.  Then, participants 
were asked to complete questionnaires on demographic and medical history data, symptoms of 
psychological distress, and were given educational materials on AFib.  Medical referrals were 
provided at the conclusion of their participation when indicated.  All mECG readings were 
assigned an initial report of ‘Normal,’ ‘Possible AFib,’ or ‘Indeterminable’ by the KardiaMobile 
device to acquire an initial AFib prevalence rate.  After study conclusion, three board-certified 
cardiologists independently reviewed each mECG reading for official adjudication and accuracy 
of an AFib study prevalence rate. 
Data analysis.  Descriptive statistics are reported for age, sex, race, marital status, level 
of education, and average household income.  Aim 1.  The chief aim of the proposed study was to 
report on the prevalence of risk factors associated with AFib, calculated stroke risk scores, and 
rates of previously diagnosed AFib in an ENC sample.  It was hypothesized that the prevalence 
of at least three AFib risk factors in a community sample would be greater than reported national 
averages.  National averages reported in the American Heart Association’s 2018 Heart Disease 
and Stroke Statistics Update (Benjamin, Virani, Callaway, Chamberlain, Chang, Cheng et al., 
2018) were used for comparison.  Chi-squared cross-tabulation methods were used to measure 
differences of weighted proportions to compare percentages of prevalence in both groups.  Power 
analyses for a chi-square test with a total sample size of 250 and a medium effect size (w = 0.3) 




sample would be greater than 2%; and the average CHA₂DS₂-VASc score would be greater than 
2 as measured by a one-sample t-test.  Means, standard deviations, relative risk ratios, and 95% 
confidence intervals are reported.  
 Aim 2.  The second aim of the proposed study was to examine which psychological 
endpoints, if any, were correlated with abnormal mECG readings and elevated CHA₂DS₂-VASc 
scores (≥ 2).  mECG readings were dichotomized into ‘Normal’ or ‘Abnormal’ categories with 
the latter group containing both ‘Possible AFib’ and ‘Indeterminable’ readings.  It was 
hypothesized that at least one psychological endpoint (depression, anxiety, or stress) would be 
correlated with abnormal mECG readings.  It was also hypothesized that at least one of the 
aforementioned psychological endpoints would be correlated with elevated CHA₂DS₂-VASc 
scores (≥ 2).  A Pearson r correlation matrix was utilized to reveal relationships between 
CHA₂DS₂-VASc component parts, abnormal mECG readings, and psychological variables.  
Power analysis for a two-tailed point-biserial correlation given 𝑎 = 0.05, medium effect size (d = 
0.3), and sample of 157 participants yielded 97% power. 
 Aim 3. The third and final aim of the study was to evaluate the predictive capabilities of 
the CHA₂DS₂-VASc component parts and their relationship(s) with abnormal mECG readings.  
It was hypothesized that each of the components of the CHA₂DS₂-VASc model would be a 
significant and independent predictor of abnormal mECG readings.  It was also hypothesized that 
the strongest psychological end-point score, when added to the pre-existing CHA₂DS₂-VASc 
component parts, would strengthen its overall predictive capability of abnormal mECG readings.  
Binary logistic regression modeling was utilized to investigate the original CHA₂DS₂-VASc 
components as predictors of abnormal mECG readings, as well as to discern the most salient 




evidenced by beta weight and significance, was then added to the original CHA₂DS₂-VASc 
component equation to measure for statistically significant changes in the chi-squared statistic 
and -2 Log likelihood.
 
 
CHAPTER 4: RESULTS 
Descriptive Analyses 
 
The current study sample included a total of 250 participants.  The mean participant age 
was 61.69 ± 15.31 with a range of 22 – 91.  The majority of participants were female (60%), 
Caucasian (83%), and married (64%).  Most participants reported completing 12 years of formal 
education and earning an annual household income averaging $50,000 - $59,999. Demographic 
data is shown in Table 2. 






African American 12% 
Caucasian 83% 
Hispanic 3% 
Native American 1% 
Other 1% 






$0 – 9,999 
$10k – 19,999 
$20k – 29,999 
$30k – 39,999 
$40k – 49,999 
$50k – 59,999 
$75k – 99,999 
$100k – 149,999 
$150k and above 




















Aim 1 - Prevalence of Risk Factors, Stroke Risk, and Rates of AFib 
 
 The primary aim of this research was to report on the prevalence of risk factors 
associated with AFib, calculated stroke risk scores, and rates of previously diagnosed AFib in an 
ENC sample.  It was hypothesized that the prevalence rates of at least three risk factors with 
AFib in a community sample would be greater than reported national averages found in the 
American Heart Association’s 2018 Heart Disease and Stroke Statistics Update (Benjamin et al., 
2018).  It was also hypothesized that prevalence rates of previously undiagnosed AFib would be 
greater than 2% and the average CHA₂DS₂-VASc score would be greater than 2. 
Chi-squared analyses of AFib risk factor prevalence rates.  Prevalence rates were 
analyzed with chi-squared cross-tabulation methods that controlled for differences in proportions 
with weighted sample sizes.  Hypothesis 1a predicted that prevalence rates of at least three major 
risk factors of stroke risk would be significantly greater in the current sample as compared to US 
national averages.  This hypothesis was confirmed as 6 of 7 risk factor scores in the community 
sample were significantly greater than national prevalence rates.  Prevalence rates, relative risk 
ratios, and chi-squared values can be found in Table 3. 
Participants in the current study had significantly higher rates of hypertension (75% of 
250) than the average US adult (35% of 252M), 2(1, N = 252,059,074) = 187.11, p < .001.  
Participants in the current study had significantly higher rates of obstructive sleep apnea (24.8% 
of 250) than the average US adult (2.5% of 252M), 2(1, N = 226,559,242) = 510.04, p < .001.  
Participants in the current study had significantly higher rates of obesity (65.2% of 250) than the 
average US adult (36.3% of 226M), 2(1, N = 257,142,857) = 90.3, p < .001.  Participants in the 
current study had significantly higher rates of type 2 diabetes (29.6% of 250) than the average 




study had significantly higher rates of peripheral vascular disease (14.8% of 250) than the 
average US adult (2.74% of 247M), 2(1, N = 247,813,910) = 136.44, p < .001.  Participants in 
the current study had significantly higher rates of previous stroke (7.6% of 250) than the average 
US adult (2.7% of 266M), 2(1, N = 266,666,667) = 22.85, p < .001.  Lastly, there were no 
significant differences in the rates of congestive heart failure (3.2% of 250) in the study sample 
compared to the average US adult (2.5% of 260M), 2(1, N = 260,000,258) = 142.9, p (two-
sided) = 0.42.   
Table 3. Prevalence of AFib Risk Factors in ENC Compared to US National Samples 





Ratio [95% CI] 
2 value 
Congestive Heart Failure 3.2% 2.5% 1.51 [0.26; 8.79] 142.9 
Hypertension 75.2% 35% 2.14 [1.61; 2.92] 187.11** 
Age ≥ 75 21.6% --- --- --- 
Diabetes Mellitus 29.6% 9.1% 3.35 [1.67; 6.66] 127.01** 
Previous Stroke / TIA 7.6% 2.7% 2.67 [0.73; 9.76] 22.85** 
Peripheral Vascular Disease 4.8% 2.7% 1.67 [0.41; 6.79] 136.44** 
Age 65 – 74 25.6% --- --- --- 
Female Sex 60.8% --- --- --- 
Obstructive Sleep Apnea 24.8% 2.5% 8.33 [2.60; 26.72] 510.04** 
Obesity 65.2% 36% 1.81 [1.34; 2.43] 90.3** 
*significant at the p < .05 level 
**significant at the p < .01 level 
 
Previously undiagnosed rates of AFib and CHA₂DS₂-VASc means.  Hypothesis 1b 
predicted that rates of previously undiagnosed AFib in the current study would be greater than 
2%, which is the average percentage found in research studies of similar scope and design 
examined in the literature.  Hypothesis 1b was supported as the KardiaMobile device discovered 
a total of 10/250 (4%) mECG readings were positive for AFib, 202/250 (81%) resulted in normal 
sinus rhythm readings, and 38/250 (15%) were indeterminable readings.  However, when the 
mECG readings were separately reviewed by three electrophysiologists, the rates of AFib were 




lead reading, a true prevalence rate of AFib in the study sample remained elusive. An overall 
range of possible AFib rates is reported between 1-8%. mECG percentages and differences in 
electrophysiologist adjudications are listed in Table 4.  
Lastly, hypothesis 1c predicted that the average CHA₂DS₂-VASc score would be greater 
than 2, which is the standard cut-off score for the recommendation of oral anti-coagulant 
treatment.  This hypothesis was also confirmed as the average CHA₂DS₂-VASc score in the 
study sample was 2.68 ± 1.35. A one-sample t-test revealed the average CHA₂DS₂-VASc score 
in the current sample (M = 2.68, SD = 1.35) to be much higher than expected averages, t(249) = 
7.96, p < .001. 
Table 4. mECG Results from KardiaMobile and Electrophysiologist (EP) Review 
EP Adjudications EP 1 EP 2 EP 3 
Possible AFib 19/250 (8%) 4/250 (2%) 2/250 (1%) 
----- ----- ----- ----- 
KardiaMobile Reading      
Sinus Rhythm 202/250 (81%)     
Unclassified 38/250 (15%)     
Possible AFib 10/250 (4%)     
 
Aim 2 - Correlations of Stroke Risk, Abnormal mECGs, and Psychological Variables 
 
 The second aim of the current study was to investigate point-biserial correlations between 
CHA₂DS₂-VASc stroke risk scores, abnormal mECG readings, and three psychological variables 
(depression, anxiety, stress symptom scores).  These correlations were completed under the 
assumption that increased CHA₂DS₂-VASc scores would be significantly correlated with 
abnormal mECG readings, which was confirmed (r = .46, p < .05) prior to additional analyses. 
 There were two hypotheses within this aim.  Hypothesis 2a predicted that at least one 
psychological endpoint (depression, anxiety, or stress symptom score) would be correlated with 




would be significantly correlated with CHA₂DS₂-VASc scores greater than or equal to 2.  Both 
of these hypotheses were rejected as no significance was found between psychological 
endpoints, abnormal mECGs, or CHA₂DS₂-VASc scores.  Point-biserial correlations and 
significance levels can be found in Table 5.  
Table 5. Correlations Between Stroke Risk, Abnormal mECG, and Psychological Variables 
  Depression Anxiety Stress 
CHA₂DS₂-VASc 
(>= 2) 
Pearson r = .042 
Sig. two-tailed = .601 
Pearson r = .046 
Sig. two-tailed = .565 
Pearson r = -.090 
Sig. two-tailed = .260 
Abnormal 
mECG 
Pearson r = -.110 
Sig. two-tailed = .169 
Pearson r = .094 
Sig. two-tailed = .242 
Pearson r = -.121 
Sig. two-tailed = .130 
*Denotes Pearson r significance at the p < .05 level 
Aim 3 - Predictive Capabilities of CHA₂DS₂-VASc on Abnormal mECG Readings 
 The third and final aim of the current study was to evaluate the predictive capabilities of 
the CHA₂DS₂-VASc component parts and their relationship(s) with abnormal mECG readings.  
mECG readings were dichotomized into ‘Normal’ or ‘Abnormal’ categories.  Abnormal mECG 
readings were comprised of ‘Possible AFib’ and ‘Indeterminable’ readings.  Hypothesis 3a 
predicted that each of the components of the CHA₂DS₂-VASc model would be significant and 
independent predictors of abnormal mECG readings.  After mECG dichotomization there were 
118 ‘Normal’ mECG readings and 39 ‘Abnormal’ mECG readings.  Hypothesis 3b predicted that 
the strongest psychological end-point score, when added to the pre-existing CHA₂DS₂-VASc 
component parts, would strengthen its overall predictive capability of abnormal mECG readings.  
Binary logistic regression modeling was utilized to test the original CHA₂DS₂-VASc components 
as predictors of abnormal mECG readings, as well as to discern the most salient psychological 




endpoint, evidenced by beta weight and significance, was then added to the original CHA₂DS₂-
VASc component equation to measure for statistically significant changes in -2 Log likelihood. 
 A binary logistic regression model with only the original components of the CHA₂DS₂-
VASc stroke risk calculator was completed first.  As expected, the model was highly predictive 
of abnormal mECG readings, χ2 (7, N = 157) = 18.73, p < .01.  However, hypothesis 3a 
predicted that each of the components of the CHA₂DS₂-VASc model would be significant and 
independent predictors of abnormal mECG readings and this hypothesis was rejected.  Only the 
risk factors of hypertension (p < .05, OR = 2.809), age (p < .05, OR = 1.032), and sex (p < .01, 
OR = 3.298) were significant, independent risk factors associated with abnormal mECG 
readings.  Full statistics on this model can be found in Table 6. 
Table 6. CHA₂DS₂-VASc Original Model: Binary Logistic Regression 
  Chi-square df Sig. -2 Log likelihood 
Step 1: Variables Step 18.73 7 0.009** 157.29 
 Block 18.73 7 0.009**  
 Model 18.73 7 0.009**  
      
 B df Sig. Exp(B) CI (95%) 
CHF .017 1 .987 1.017 [.129, 8.013] 
HTN 1.033 1 .032* 2.809 [1.093, 7.216] 
Age .032 1 .040* 1.032 [1.001, 1.064] 
DM2 .461 1 .317 1.585 [.643, 3.907] 
Sex 1.193 1 .008** 3.298 [1.360, 8.000] 
Vasc. Disease -.248 1 .631 .283 [.283, 2.150] 
Previous Stroke -.283 1 .698 .180 [.180, 3.151] 
*Denotes significance at the p < .05 level 
**Denotes significance at the p < .01 level 
***Denotes significance at the p <.001 level 
 
Then, a binary logistic regression model with both the original components of the 
CHA₂DS₂-VASc stroke risk calculator and symptoms scores for depression, anxiety, and stress 




most salient psychological endpoint, as well as to determine if the addition of these 
psychological factors improved the predictive capability of the model. The model was 
strengthened significantly as evidenced by an increase in the chi-squared statistic, χ2 (10, N = 
157) = 37.705, p < .001 and reduction in -2 Log likelihood (157.29 to 138.317). In this model 
inclusive of all three psychological endpoints, the variables of hypertension (p < .05, OR = 
3.428), sex (p < .01, OR = 4.149), and anxiety (p < .001, OR = 1.235) were the most significant 
predictors of abnormal mECG readings. Full statistics for this model can be found in Table 7. 
Table 7. CHA₂DS₂-VASc Model + DAS Variables: Binary Logistic Regression 
  Chi-square df Sig. -2 Log likelihood 
Step 1: Variables Step 18.972 3 < .001*** 138.317 
 Block 18.972 3 < .001***  
 Model 37.705 10 < .001***  
      
 B df Sig. Exp(B) CI (95%) 
CHF -.289 1 .797 .749 [.083, 6.754] 
HTN 1.232 1 .020* 3.428 [1.212, 9.698] 
Age .026 1 .124 1.026 [.993, 1.060] 
DM2 .649 1 .197 1.915 [.714, 5.132] 
Sex 1.423 1 .005** 4.149 [1.543, 11.160] 
Vasc. Disease -.090 1 .875 .914 [.296, 2.823] 
Previous Stroke -.501 1 .557 .606 [.114, 3.226] 
DEPRESSION  -.098 1 .108 .906 [.804, 1.022] 
ANXIETY .211 1 .000*** 1.235 [1.104, 1.382] 
STRESS -.101 1 .058 .904 [.814, 1.003] 
*Denotes significance at the p < .05 level 
**Denotes significance at the p < .01 level 
***Denotes significance at the p <.001 level 
 
Lastly, a binary logistic regression model with both the original components of the 
CHA₂DS₂-VASc stroke risk calculator and an anxiety symptom score were completed. 
Hypothesis 3b predicted that the strongest psychological end-point score, when added to the pre-
existing CHA₂DS₂-VASc component parts, would strengthen its overall predictive capability of 




including the anxiety score was not as strong as the model that included all three psychological 
endpoints. The addition of an anxiety endpoint alone significantly improved the predictive 
capability of the model as evidence by an increase in the chi-squared statistic, χ2 (8, N = 157) = 
22.967, p < .01 and reduction in -2 Log likelihood (157.29 to 153.055). In this model including 
an anxiety symptom score endpoint, the variables of hypertension (p < .05, OR = 2.809), age (p < 
.05, OR = 1.032), sex (p < .01, OR = 3.298), and anxiety (p < .05, OR = 1.060) were the most 
significant predictors of abnormal mECG readings. Full statistics for this model can be found in 
Table 8. 
Table 8. CHA₂DS₂-VASc Model + ANX: Binary Logistic Regression 
  Chi-square df Sig. -2 Log likelihood 
Step 1: Variables Step 4.234 1 .040* 153.055 
 Block 4.234 1 .040*  
 Model 22.967 8 .003**  
      
 B df Sig. Exp(B) CI (95%) 
CHF .071 1 .948 1.017 [.126, 9.116] 
HTN 1.196 1 .018* 2.809 [1.231, 8.887] 
Age .037 1 .021* 1.032 [1.006, 1.071] 
DM2 .459 1 .318 1.585 [.643, 3.894] 
Sex 1.338 1 .004** 3.298 [1.528, 9.514] 
Vasc. Disease -.083 1 .877 .283 [.322, 2.635] 
Previous Stroke -.324 1 .664 .180 [.167, 3.124] 
ANXIETY .058 1 .034* 1.060 [1.004, 1.118] 
*Denotes significance at the p < .05 level 
**Denotes significance at the p < .01 level 
***Denotes significance at the p <.001 level
 
 
CHAPTER 5: DISCUSSION 
Summary of Findings 
The purposes of the current study included broad, community-wide aims and also 
exploratory methods of integrating psychological factors into traditional ischemic stroke risk 
prediction. The primary aim of the study was to examine the base rates of known risk factors 
associated with AFib, to determine the average CHA₂DS₂-VASc stroke risk scores, and to 
uncover the rates of previously undiagnosed AFib in an ENC community sample (N = 250). The 
secondary aims were to evaluate the relationships between self-reported psychological symptoms 
and correlates of AFib and its risk factors (N = 157). The third aim was to evaluate predictors of 
abnormal mECG readings (N = 157).  
The current study produced several meaningful findings from offering single-lead mECG 
readings to an opportunistic sample of individuals presenting to their local pharmacies. The rates 
of previously undiagnosed AFib were much higher than rates found in studies of similar scope 
and design. Preliminary AFib rates of approximately 4% based on KardiaMobile mECG readings 
were blindly and independently reviewed by board-certified electrophysiologists, revealing an 
AFib prevalence rate ranging from 1-8% dependent upon the reviewer. This number represents a 
rate of previously undiagnosed AFib that is unmatched in similar literature. Not only were AFib 
rates higher than expected, the participants’ average CHA₂DS₂-VASc scores were greater than 2 
(2.68 ± 1.35) signifying an alarming rate of often untreated ischemic stroke risk in a community 
sample. Additionally, the prevalence rates of six, known independent stroke risk factors were 
also significantly higher in the study sample than reported national US averages.  
Significant correlations were not found between psychological endpoints and abnormal 




revealed that a longstanding stroke risk calculator could be potentially strengthened with the 
addition of one (anxiety) or three (depression, anxiety, and stress) psychological endpoints. 
These results represent novel findings with broad implications for community AFib screening. 
These results suggest that the addition of psychological endpoints may have a value-added effect 
on an established stroke risk calculator to predict ischemic stroke risk. 
The CHA₂DS₂-VASc stroke risk calculator will continue to require updating based on 
dynamic health trends found in the US population. Further independent risk factors for stroke 
that will likely be added to the CHA₂DS₂-VASc calculator include obesity and obstructive sleep 
apnea. This research makes an inaugural argument for the addition of a psychological endpoint 
to be included in the CHA₂DS₂-VASc calculator. The biopsychosocial relationships between 
psychological symptoms and cardiovascular outcomes continue to be established, but there is 
ample preliminary evidence to support the further investigation of possible direct and indirect 
links between poor psychological health and increased ischemic stroke risk.  
HRS Summary Report 
 The current study was part of a larger AFib screening and education initiative conducted 
by the Heart Rhythm Society (HRS). The initiative had two primary goals:  to encourage 
innovative screening for AFib and to provide education to local communities about the risks 
associated with AFib. East Carolina University’s Department of Psychology was one of eight 
locations chosen to conduct mECG community screenings and one of six sites to fulfill all 
project requirements. HRS provided an internal summary report based on the 1,383 individuals 
screened across all sites. Positive AFib readings taken by a KardiaMobile device were found in 




(70.5%), followed by obesity (39.3%) and type 2 diabetes (27.7%). More information on this 
initiative can be found in Tables 9 and 10.  
Table 9. Site Characteristics from the HRS AFib Screening Summary Report 
Site Region Participants Indeterminable Possible AFib 
     
University of Buffalo Buffalo, NY 141 Not reported 9 
East Carolina University Greenville, NC 250 37 10 
Edwards-Elmhurst Healthcare Chicago, IL 262 35 10 
Mayo Clinic Rochester, MN 229 19 1 
University of Massachusetts Worcester, MA 250 23 7 
Wellness Center of Eastern ID Idaho Falls, ID 251 12 2 
     
 Total 1383 126 39 
     
 mECG %  9.10% 2.80% 
 
Table 10. Site Reported Risk Factors from the HRS AFib Screening Summary Report 
Site Age > 75 years DM2 Female HTN Obesity PVD OSA 
        
University of Buffalo 139 39 116 117 9 66 2 
East Carolina University 54 74 152 188 163 37 62 
Edwards-Elmhurst Healthcare 226 37 205 166 61 42 23 
Mayo Clinic 140 63 204 169 104 10 67 
University of MA 80 79 98 191 108 42 5 
Wellness Center of Eastern ID 17 91 178 144 98 12 86 
        
Total 656 383 953 975 543 209 245 
% of Total Screened 47.40% 27.70% 68.90% 70.50% 39.30% 15.10% 17.70% 
 
Considerations for Community Screening  
 
 The utilization of novel screening techniques for AFib continues to be proven as a safe, 
convenient, cost-saving, and potentially life-saving way to prevent patients from experiencing a 
stroke. Practical and philosophical questions remain about how and why to use technology such 
as AliveCor’s KardiaMobile device to detect the presence of AFib. The obvious benefits include 




contributor to overall stroke risk and its early detection is an effective preventive strategy for 
mitigating overall stroke risk. The interventions of anticoagulation, ablation, and use of 
antiarrhythmic medications prevent stroke incidence and are usually initiated by an AFib 
diagnosis. The psychological impact of novel, mobile-based screening for AFib appears to be 
minimal. Patients and families have reported that the technology is easy to use, increases their 
healthcare confidence, and can give them peace of mind (Kropp et al., 2018).  
 There are also downsides to increased screening for AFib. In some instances, AFib 
screening may seem unnecessary or even burdensome to patients. These screenings can also 
potentially increase health-related anxiety in a small subset of patients due the desire for 
increased health-related hypervigilance and amplified checking behaviors. From a healthcare 
point of view, these additional screenings may increase the workload of medical practitioners by 
creating a more constant stream of medical information requiring review. A perfect balance 
between utilization of this technology and integration into complex medical systems is still being 
pursued and represents a significant challenge. However, some universal truths are beginning to 
emerge and are also evidenced by the results of the current study. 
 Devices such as KardiaMobile are most useful when used in screening initiatives 
targeting individuals with 1-2 known risk factors for AFib, and this technology allows for more 
routine screening that can better capture AFib episodes from outside a medical facility 
(Rosenfeld, Alpesh, Hsu, Oxner, Hills, Frankel, 2019). These benefits of using these 1-lead 
recordings are undoubtedly enhanced by immediate confirmation via 12-lead ECG when 
possible. At-home or community screening methods may also increase patient engagement in 
their own healthcare and give patients and their families an increased sense of control (Rosenfeld 





AFib is a growing health crisis that affects different regions and groups 
disproportionately. Known as one the leading risk factors for increased frequency and severity of 
ischemic stroke, AFib risk is comprised of several co-morbid risk factors that commonly exist in 
areas with low access to healthcare, increased levels of poverty, and decreased level of health 
literacy. Because of these barriers and others, this condition is often under-diagnosed, and 
symptoms may be inconsistent or misattributed to other disease states. Traditional means of AFib 
identification including 12-lead ECG often elude individuals in rural settings, making the design 
of the current study novel and participant-centered. 
Unprecedented levels of previously undiagnosed AFib in the study sample further 
highlight the ENC region’s unmet medical needs and increased levels of co-morbid disease 
states. The estimated base rates of AFib found in the current study further justify the use of 
novel, mECG technology to screen for AFib in at-risk populations. There is increasing evidence 
to suggest that more US adults have AFib than is reported. A multi-center randomized controlled 
trial of almost exactly the same sample size recently reported that individuals with AFib-related 
symptoms using mECG technology across a 90-day period were five times more likely to capture 
at least one episode of AFib (Reed et al., 2019). Because AFib is so strongly linked to ischemic 
stroke, it is imperative that this type of arrhythmia is detected and treated as early as possible. 
mECG technology represents a low-cost, non-invasive solution to this problem. 
The results of the current study provide evidence to support the practice of opportunistic 
community screening for previously undiagnosed AFib in at-risk populations. Medical 
technology development and the burgeoning field of at-home digital health screening may 




prior to their existence on the consumer market. However, a growing body of research points to 
mECG technology as a low-cost, non-invasive, safe strategy to reduce overall cardiovascular 
disease burden in the US.  
 There are still several questions that remain about the diagnostic implementation of these 
devices. At-home screening is convenient but may not be indicated for all consumers, and not all 
individuals will want to pay the fees commonly associated with on-demand cardiologist 
interpretation. This technology may be best utilized in peripheral medical settings such as 
pharmacies and nursing homes where screenings can be initiated by either patient or health staff. 
Regulations and standards of use for these devices are still in their infancy, but the potential 
upside of catching AFib symptoms sooner in the general population far outweigh the 
disadvantages and difficulties associated with questions of implementation, feasibility, and cost-
effectiveness. 
Psychological Determinants of Health 
Many studies have now investigated the accuracy and practicality of using mECG 
devices. To the authors’ knowledge, the current study is the first of its kind to investigate 
psychological improvements to the CHA₂DS₂-VASc stroke risk calculator. Our results are only 
preliminary but warrant further investigation of adding psychological components to the 
measurement of stroke risk. The symptoms associated with depression, anxiety, and stress have 
been demonstrated in the literature to be linked to, at the very least, the exacerbation of common 
cardiovascular symptoms. These psychological factors are pervasive to mental, physical, and 
behavioral components of individuals’ health and should continue to be investigated as potential 






 The current study was impacted by several limitations common to novel study designs. 
The first limitation is a caveat that should be taken into consideration when interpreting the 
positive AFib readings described in the results section. Our study recorded an 8% positive AFib 
rate among our participants, but these readings were taken by a 1-lead mECG device and were 
not confirmed via 12-lead ECG. However, they were blindly adjudicated by three, independent 
cardiologists improving the perceived accuracy of our findings. Inter-rater reliability was a 
barrier to the identification of a true prevalence rate of AFib, as was the research team’s inability 
to immediately confirm each mECG reading with a 12-lead ECG. 
Participant recruitment took place at rural pharmacy locations. It could be assumed that a 
research sample presenting to pharmacy locations may be ‘sicker’ than a study sample from the 
general public. However, recruitment included individuals presenting to the pharmacy for 
medication purchase, as well as those shopping for household items commonly found in 
community pharmacies. Lastly, participant selection and prevalence rates of AFib risk factors 
were determined by participant self-report and were not confirmed via medical record review. 
So, it is possible that our research included participants who were not aware of a prior AFib 
diagnosis or over- or under-reported known risk factors. 
The current study included a majority of female participants, which may have elevated 
the average stroke risk score due to the automatic 1-point value of being a female on the stroke 
risk calculator. Females in the US also live longer which may have also contributed to additional 






Conclusion & Future Directions 
 The current study contains important implications for the ENC region and beyond. The 
burden of stroke on individuals and their healthcare systems is well-documented, and stroke 
survivors are affected by a wider of disabilities than most other disease populations (Adamson, 
Beswick, Ebrahim, 2004). Reports approximate that up to 80% of all strokes could be avoided 
with the mitigation of associated risk factors (National Stroke Association, 2016). The risk 
factors of stroke including AFib are relatively well-known and studied by medical professionals, 
and the list of modifiable risk factors is much longer than the list of non-modifiable risk factors. 
AFib is thought to be generally manageable or even prevented with targeted identification and 
treatment. Low access, cultural norms, and maladaptive health behaviors are all regional barriers 
to treatment. Preventive medical solutions and novel modes of intervention will continue to be 
required to reach our region’s vulnerable population.  
The future health of individuals in the ENC region depends on the coordinated efforts of 
healthcare systems and area-specific inventions that are broadly accessible by even the most 
unreachable patients. mECG technology and other remote monitoring devices have the potential 
of more quickly identifying the precipitants of disease so that interventions can occur before a 
disabling medical event occurs. The current study represents a small step forward to a future of 
enhanced diagnostic capability and treatment of potentially deadly cardiovascular diseases. 
One possible way to enhance the identification of AFib in the ENC region and beyond is 
to continue to investigate the relationships between psychological distress and maladaptive 
cardiovascular outcomes. The current study provides compelling preliminary data to suggest that 




of abnormal ECGs and thus cardiovascular abnormalities than other known independent risk 
factors. 
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Appendix B:  Measures 
To the best of your knowledge, have you ever been given a diagnosis of Atrial 
Fibrillation or Atrial Flutter? [circle one] 
 




Please indicate which of the following, if any, risk factors you have currently: 
 
^(1) _________Do you identify as female 
^(2) _________Are you 75-years old, or older? 
_________Sleep Apnea 
^(1) _________Vascular Disease  
^(1) _________Diabetes 
_________Obesity 
^(1) _________High blood pressure (hypertension) 
 
^(1) _________Congestive Heart Failure 
^(2) _________Previous Stroke, TIA, or TE 




Administrative Use Only: 
CHA2DS2-VASc score =  _______ / 9 (maximum) 
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